Lifeboat Foundation

Bioengineering professor Manu Prakash runs a lab at Stanford University that uses low-cost materials to create effective scientific devices. He returned from a recent vacation with some scuba gear — as well as a cold. While he tested negative for COVID-19, he stayed cautious and self-quarantined for two weeks. During that time, he reworked his snorkel mask into a reusable face shield for healthcare providers by combining it with a medical-grade filter. Dubbed the Pneumask, Prakash and his team tested the device and sent their findings to the FDA, which cleared it as a face shield or surgical mask, but not as a respirator. According to The Washington Post, this decision was made so that the masks could go out to healthcare workers immediately, as clearing the device as a respirator would require more time.

Manu Prakash and his team at Stanford University have turned a standard scuba mask into a reusable medical face mask.

In November of 2019—likely, even earlier—a tiny entity measuring just a few hundred billionths of a meter in diameter began to tear apart human society on a global scale. Within a few months, the relentless voyager known as SARS-CoV-2 had made its way to every populated corner of the earth, leaving scientists and health authorities with too many questions and few answers.

Today, researchers are scrambling to understand where and how the novel coronavirus arose, what features account for the puzzling constellation of symptoms it can cause and how the wildfire of transmission may be brought under control. An important part of this quest will involve efforts to properly classify this emergent human pathogen and to understand how it relates to other viruses we may know more about.

In a consensus statement, Arvind Varsani, a molecular virologist with ASU’s Biodesign Center for Fundamental and Applied Microbiomics and a host of international collaborators propose a new classification system, capable of situating coronaviruses like SARS-CoV-2 within the enormous web of viruses across the planet, known as the virosphere.

Synthetic biology has been described as a kind of “genetic engineering on steroids”.

Synthetic biology …Simply mentioning this term — whether at a cocktail party or on a pop culture TV show — evokes a plethora of responses. These could range from puzzled looks to questions about the somewhat famous, though likely quixotic, quest to resurrect a woolly mammoth from remnants recovered in Siberia. Also, on the radar screen is synthetic biology as applied to the development of drugs and biological weapons. But flying below the radar — and, oddly, the sweet spot for investments by governments and private industry — is a less sexy focus on the industrial uses of synthetic biology. Such uses range from environmental clean-ups to new energy sources.

Continue reading “Why synthetic biology is about much more than resurrecting woolly mammoths” »

An inexpensive assay based on the technique can provide yes or no answers in under an hour—perhaps even in the home soon.

Now, scientists at Washington University in St. Louis have developed a way to use gene editing system CRISPR-Cas9 to edit a mutation in human-induced pluripotent stem cells (iPSCs) and then turn them into beta cells. When transplanted into mice, the cells reversed preexisting diabetes in a lasting way, according to results published in the journal Science Translational Medicine.

While the researchers used cells from patients with Wolfram syndrome—a rare childhood diabetes caused by mutations in the WFS1 gene—they argue that the combination of a gene therapy with stem cells could potentially treat other forms of diabetes as well.

Virtual Event

Engineering researchers developed a next-generation miniature lab device that uses magnetic nano-beads to isolate minute bacterial particles that cause diseases. Using this new technology improves how clinicians isolate drug-resistant strains of bacterial infections and difficult-to-detect micro-particles such as those making up Ebola and coronaviruses.

Ke Du and Blanca Lapizco-Encinas, both faculty-researchers in Rochester Institute of Technology’s Kate Gleason College of Engineering, worked with an international team to collaborate on the design of the new system — a microfluidic device, essentially a lab-on-a-chip.

Drug-resistant bacterial infections are causing hundreds of thousands of deaths around the world every year, and this number is continuously increasing. Based on a report from the United Nations, the deaths caused by antibiotics resistance could reach to 10 million annually by 2050, Du explained.

Shahrad Daraeikia, Jack Wang, and Dr. Jean-Philippe Buerckert sit down together with Harry Glorikian at MoneyBall Medicine to talk about our ultra rapid antibody discovery race to a cure for COVID19.

Episode Summary

Continue reading “How Data Is Critical to Engineering Antibodies to Block COVID-19” »

Two new studies by researchers in Tel Aviv University and Harvard University on the subject were published in the journal Nature Biomedical Engineering on Monday.

Organs-on-a-chip were first developed in 2010 at Harvard University. Then, scientists took cells from a specific human organ — heart, brain, kidney and lung — and used tissue engineering techniques to put them in a plastic cartridge, or the so called chip. Despite the use of the term chip, which often refers to microchips, no computer parts are involved here.

Get The Start-Up Israel’s Daily Start-Up by email and never miss our top stories Free Sign Up.

UC San Francisco researchers have discovered how a mutation in a gene regulator called the TERT promoter—the third most common mutation among all human cancers and the most common mutation in the deadly brain cancer glioblastoma—confers “immortality” on tumor cells, enabling the unchecked cell division that powers their aggressive growth.

The research, published September 10, 2018 in Cancer Cell, found that patient-derived glioblastoma cells with TERT promoter mutations depend on a particular form of a protein called GABP for their survival. GABP is critical to the workings of most cells, but the researchers discovered that the specific component of this protein that activates mutated TERT promoters, a subunit called GABP-ß1L, appears to be dispensable in normal cells: Eliminating this subunit using CRISPR-based gene editing dramatically slowed the growth of the human cancer cells in lab dishes and when they were transplanted into mice, but removing GABP-ß1L from healthy cells had no discernable effect.

“These findings suggest that the ß1L subunit is a promising new drug target for aggressive glioblastoma and potentially the many other cancers with TERT promoter mutations,” said study senior author Joseph Costello, Ph.D., a leading UCSF neuro-oncology researcher.